Share Price and Basic Stock Data
Last Updated: January 29, 2026, 6:31 pm
| PEG Ratio | -16.97 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lotus Eye Hospital & Institute Ltd operates in the Hospitals & Medical Services industry, with a current market capitalization of ₹281 Cr and a share price of ₹135. The company has shown a steady growth in revenue, with sales increasing from ₹38.90 Cr in March 2022 to ₹47.03 Cr in March 2023, and further to ₹48.20 Cr in March 2024. This upward trend continued with a TTM revenue of ₹50.32 Cr. Quarterly sales figures reflect a fluctuating yet positive trajectory, peaking at ₹12.91 Cr in September 2024, and indicating resilience despite minor dips. The operating profit margin (OPM) stood at 5.90% for the latest reporting period, reflecting operational efficiency challenges compared to typical sector margins, which often range higher. The company’s sales growth, while commendable, should be contextualized against the backdrop of increasing operational expenses, which rose from ₹39.35 Cr in March 2023 to ₹41.57 Cr in March 2024, indicating a need for improved cost management strategies.
Profitability and Efficiency Metrics
Lotus Eye Hospital’s profitability metrics reveal a mixed performance. The net profit for the fiscal year ending March 2025 was ₹0.74 Cr, a decline from ₹2.91 Cr in March 2024. This decline is mirrored in the earnings per share (EPS), which fell to ₹0.36 from ₹1.40 in the previous year. The company’s return on equity (ROE) stood at a modest 1.22%, while the return on capital employed (ROCE) was recorded at 2.99%. The interest coverage ratio (ICR) of 13.34x indicates that the company comfortably meets its interest obligations, a positive sign for its financial health. However, the operating profit margin has seen volatility, with the latest figure at 5.90%. The cash conversion cycle (CCC) of 33.48 days points to efficiency in converting investments into cash flows, although the inventory days have increased significantly to 193.62 days in March 2025, suggesting potential inefficiencies in inventory management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Lotus Eye Hospital reveals a cautious financial stance, with total assets amounting to ₹69.57 Cr as of March 2025. The company holds reserves of ₹39.82 Cr, alongside borrowings of ₹4.80 Cr, indicating a conservative leverage strategy. The current ratio is 1.56, above the typical threshold of 1.00, suggesting adequate liquidity to cover short-term liabilities. The price-to-book value (P/BV) ratio stands at 2.42x, reflecting a premium valuation compared to the book value of ₹28.85 per share, indicating investor confidence despite the lower profitability metrics. The inventory turnover ratio of 14.08x suggests effective inventory management, albeit the rising inventory days could pose a risk if not addressed. The interest coverage ratio of 13.34x highlights the firm’s ability to manage debt effectively, yet the declining net profit margins, reported at 1.49%, raise concerns about long-term sustainability.
Shareholding Pattern and Investor Confidence
Investor confidence in Lotus Eye Hospital is reflected in its shareholding pattern, where promoters hold 40.63% of the company as of September 2025, a decline from higher levels earlier in the year. The public holds a significant 59.33% stake, indicating robust retail interest, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) have negligible stakes at 0.00% and 0.02%, respectively. The number of shareholders has fluctuated, with a notable increase to 10,777 by September 2025, suggesting growing retail participation. The decline in promoter holding could signal potential concerns regarding management confidence or strategic shifts. Despite this, the public’s substantial stake may provide a buffer against volatility, although the lack of institutional backing could be a risk factor. This uneven distribution of shares may result in challenges in governance and strategic decision-making in the future.
Outlook, Risks, and Final Insight
The outlook for Lotus Eye Hospital presents a mixed picture, characterized by growth potential tempered by significant operational challenges. The company’s ability to enhance profitability amidst rising expenses and declining net profits is crucial for future performance. Key risks include the volatility in operating margins and the increasing inventory days, which could impact cash flow if not managed effectively. Additionally, the decline in promoter shareholding raises questions about management confidence and strategic direction, potentially influencing investor sentiment. On the positive side, the company’s solid interest coverage ratio and liquidity position provide a buffer against short-term financial distress. As the healthcare sector continues to evolve, Lotus Eye must implement robust cost-control measures and enhance operational efficiencies to leverage growth opportunities effectively. The company’s focus on improving profitability metrics and maintaining investor confidence will be pivotal in navigating the competitive landscape ahead.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Dr Lalchandani Labs Ltd | 15.2 Cr. | 17.6 | 21.2/7.24 | 32.4 | 11.7 | 0.00 % | 2.81 % | 3.08 % | 10.0 |
| Asarfi Hospital Ltd | 340 Cr. | 173 | 221/72.9 | 24.2 | 45.2 | 0.00 % | 15.8 % | 14.1 % | 10.0 |
| Narayana Hrudayalaya Ltd | 35,632 Cr. | 1,743 | 2,372/1,291 | 41.9 | 199 | 0.26 % | 20.8 % | 24.2 % | 10.0 |
| Lotus Eye Hospital & Institute Ltd | 294 Cr. | 141 | 141/55.0 | 439 | 29.2 | 0.00 % | 2.99 % | 1.22 % | 10.0 |
| Industry Average | 12,088.67 Cr | 518.65 | 134.38 | 71.28 | 0.07% | 10.60% | 10.65% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11.86 | 12.14 | 11.17 | 12.57 | 12.73 | 12.03 | 10.88 | 12.89 | 12.91 | 12.25 | 11.51 | 13.52 | 13.04 |
| Expenses | 10.10 | 10.03 | 9.78 | 10.18 | 10.92 | 10.45 | 10.12 | 11.23 | 11.76 | 11.46 | 11.68 | 12.04 | 12.27 |
| Operating Profit | 1.76 | 2.11 | 1.39 | 2.39 | 1.81 | 1.58 | 0.76 | 1.66 | 1.15 | 0.79 | -0.17 | 1.48 | 0.77 |
| OPM % | 14.84% | 17.38% | 12.44% | 19.01% | 14.22% | 13.13% | 6.99% | 12.88% | 8.91% | 6.45% | -1.48% | 10.95% | 5.90% |
| Other Income | 0.23 | 0.32 | 0.36 | 0.29 | 0.28 | 0.34 | 0.40 | 0.31 | 0.27 | 0.22 | 0.52 | 0.19 | 0.27 |
| Interest | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.04 | 0.03 | 0.06 | 0.08 | 0.13 | 0.09 | 0.12 | 0.12 |
| Depreciation | 0.75 | 0.77 | 0.78 | 0.73 | 0.89 | 0.98 | 1.12 | 1.06 | 1.23 | 1.31 | -0.58 | 0.82 | 0.85 |
| Profit before tax | 1.21 | 1.64 | 0.95 | 1.93 | 1.19 | 0.90 | 0.01 | 0.85 | 0.11 | -0.43 | 0.84 | 0.73 | 0.07 |
| Tax % | 24.79% | 29.88% | 31.58% | 27.98% | 28.57% | 26.67% | -200.00% | 28.24% | 9.09% | -44.19% | 70.24% | 24.66% | -71.43% |
| Net Profit | 0.90 | 1.16 | 0.65 | 1.38 | 0.85 | 0.66 | 0.02 | 0.62 | 0.10 | -0.24 | 0.25 | 0.54 | 0.12 |
| EPS in Rs | 0.43 | 0.56 | 0.31 | 0.66 | 0.41 | 0.32 | 0.01 | 0.30 | 0.05 | -0.12 | 0.12 | 0.26 | 0.06 |
Last Updated: January 11, 2026, 2:58 pm
Below is a detailed analysis of the quarterly data for Lotus Eye Hospital & Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 13.04 Cr.. The value appears to be declining and may need further review. It has decreased from 13.52 Cr. (Jun 2025) to 13.04 Cr., marking a decrease of 0.48 Cr..
- For Expenses, as of Sep 2025, the value is 12.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.04 Cr. (Jun 2025) to 12.27 Cr., marking an increase of 0.23 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.77 Cr.. The value appears to be declining and may need further review. It has decreased from 1.48 Cr. (Jun 2025) to 0.77 Cr., marking a decrease of 0.71 Cr..
- For OPM %, as of Sep 2025, the value is 5.90%. The value appears to be declining and may need further review. It has decreased from 10.95% (Jun 2025) to 5.90%, marking a decrease of 5.05%.
- For Other Income, as of Sep 2025, the value is 0.27 Cr.. The value appears strong and on an upward trend. It has increased from 0.19 Cr. (Jun 2025) to 0.27 Cr., marking an increase of 0.08 Cr..
- For Interest, as of Sep 2025, the value is 0.12 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.12 Cr..
- For Depreciation, as of Sep 2025, the value is 0.85 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Jun 2025) to 0.85 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.73 Cr. (Jun 2025) to 0.07 Cr., marking a decrease of 0.66 Cr..
- For Tax %, as of Sep 2025, the value is -71.43%. The value appears to be improving (decreasing) as expected. It has decreased from 24.66% (Jun 2025) to -71.43%, marking a decrease of 96.09%.
- For Net Profit, as of Sep 2025, the value is 0.12 Cr.. The value appears to be declining and may need further review. It has decreased from 0.54 Cr. (Jun 2025) to 0.12 Cr., marking a decrease of 0.42 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.06. The value appears to be declining and may need further review. It has decreased from 0.26 (Jun 2025) to 0.06, marking a decrease of 0.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:03 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.69 | 29.90 | 31.13 | 33.96 | 38.02 | 38.43 | 40.55 | 32.35 | 38.90 | 47.03 | 48.20 | 49.55 | 50.32 |
| Expenses | 25.40 | 27.72 | 27.14 | 30.63 | 33.68 | 35.21 | 36.57 | 28.73 | 32.98 | 39.35 | 41.57 | 45.99 | 47.45 |
| Operating Profit | 3.29 | 2.18 | 3.99 | 3.33 | 4.34 | 3.22 | 3.98 | 3.62 | 5.92 | 7.68 | 6.63 | 3.56 | 2.87 |
| OPM % | 11.47% | 7.29% | 12.82% | 9.81% | 11.42% | 8.38% | 9.82% | 11.19% | 15.22% | 16.33% | 13.76% | 7.18% | 5.70% |
| Other Income | 0.39 | 0.46 | 0.58 | 0.68 | 0.91 | 0.68 | 0.21 | 0.84 | 0.88 | 1.15 | 1.31 | 1.31 | 1.20 |
| Interest | 0.04 | 0.10 | 0.16 | 0.15 | 0.18 | 0.21 | 0.24 | 0.14 | 0.21 | 0.20 | 0.20 | 0.48 | 0.46 |
| Depreciation | 3.54 | 4.76 | 4.44 | 3.44 | 3.37 | 3.06 | 2.50 | 2.33 | 2.50 | 2.98 | 3.73 | 3.01 | 2.40 |
| Profit before tax | 0.10 | -2.22 | -0.03 | 0.42 | 1.70 | 0.63 | 1.45 | 1.99 | 4.09 | 5.65 | 4.01 | 1.38 | 1.21 |
| Tax % | 60.00% | -10.81% | -400.00% | -7.14% | -2.35% | -12.70% | 26.90% | 21.11% | 27.14% | 27.79% | 27.43% | 46.38% | |
| Net Profit | 0.04 | -1.98 | 0.10 | 0.44 | 1.75 | 0.71 | 1.06 | 1.57 | 2.98 | 4.08 | 2.91 | 0.74 | 0.67 |
| EPS in Rs | 0.02 | -0.95 | 0.05 | 0.21 | 0.84 | 0.34 | 0.51 | 0.75 | 1.43 | 1.96 | 1.40 | 0.36 | 0.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 236.36% | 59.43% | 0.00% | 0.00% | 66.24% | 34.90% | 25.49% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -5050.00% | 105.05% | 340.00% | 297.73% | -59.43% | 49.30% | 48.11% | 89.81% | 36.91% | -28.68% | -74.57% |
| Change in YoY Net Profit Growth (%) | 0.00% | 5155.05% | 234.95% | -42.27% | -357.16% | 108.72% | -1.18% | 41.70% | -52.90% | -65.59% | -45.89% |
Lotus Eye Hospital & Institute Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 4% |
| 3 Years: | 8% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -13% |
| 3 Years: | -38% |
| TTM: | -70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 33% |
| 3 Years: | 25% |
| 1 Year: | 61% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 9:50 am
Balance Sheet
Last Updated: December 4, 2025, 1:34 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 | 20.80 |
| Reserves | 30.57 | 28.59 | 28.69 | 29.26 | 29.84 | 29.32 | 30.46 | 31.90 | 33.81 | 36.78 | 38.61 | 39.20 | 39.82 |
| Borrowings | 0.18 | 0.83 | 0.66 | 0.48 | 0.29 | 0.22 | 0.32 | 0.40 | 1.24 | 0.67 | 1.11 | 3.43 | 4.80 |
| Other Liabilities | 7.01 | 6.20 | 4.68 | 4.40 | 7.28 | 6.18 | 6.53 | 6.12 | 5.75 | 4.93 | 6.11 | 6.14 | 6.09 |
| Total Liabilities | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.60 | 63.18 | 66.63 | 69.57 | 71.51 |
| Fixed Assets | 46.94 | 47.04 | 43.57 | 41.32 | 42.52 | 44.14 | 42.67 | 40.54 | 44.07 | 44.18 | 48.65 | 54.07 | 55.17 |
| CWIP | 0.36 | 0.27 | 0.42 | 0.65 | 0.29 | 0.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.06 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 11.26 | 9.11 | 10.84 | 12.97 | 15.40 | 12.09 | 15.44 | 18.68 | 17.53 | 19.00 | 17.90 | 15.50 | 16.28 |
| Total Assets | 58.56 | 56.42 | 54.83 | 54.94 | 58.21 | 56.52 | 58.11 | 59.22 | 61.60 | 63.18 | 66.63 | 69.57 | 71.51 |
Below is a detailed analysis of the balance sheet data for Lotus Eye Hospital & Institute Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 20.80 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.80 Cr..
- For Reserves, as of Sep 2025, the value is 39.82 Cr.. The value appears strong and on an upward trend. It has increased from 39.20 Cr. (Mar 2025) to 39.82 Cr., marking an increase of 0.62 Cr..
- For Borrowings, as of Sep 2025, the value is 4.80 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 3.43 Cr. (Mar 2025) to 4.80 Cr., marking an increase of 1.37 Cr..
- For Other Liabilities, as of Sep 2025, the value is 6.09 Cr.. The value appears to be improving (decreasing). It has decreased from 6.14 Cr. (Mar 2025) to 6.09 Cr., marking a decrease of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 71.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 69.57 Cr. (Mar 2025) to 71.51 Cr., marking an increase of 1.94 Cr..
- For Fixed Assets, as of Sep 2025, the value is 55.17 Cr.. The value appears strong and on an upward trend. It has increased from 54.07 Cr. (Mar 2025) to 55.17 Cr., marking an increase of 1.10 Cr..
- For CWIP, as of Sep 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.06 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 16.28 Cr.. The value appears strong and on an upward trend. It has increased from 15.50 Cr. (Mar 2025) to 16.28 Cr., marking an increase of 0.78 Cr..
- For Total Assets, as of Sep 2025, the value is 71.51 Cr.. The value appears strong and on an upward trend. It has increased from 69.57 Cr. (Mar 2025) to 71.51 Cr., marking an increase of 1.94 Cr..
Notably, the Reserves (39.82 Cr.) exceed the Borrowings (4.80 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 3.11 | 1.35 | 3.33 | 2.85 | 4.05 | 3.00 | 3.66 | 3.22 | 4.68 | 7.01 | 5.52 | 0.13 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 4.96 | 4.27 | 5.98 | 7.31 | 10.94 | 7.22 | 5.94 | 8.35 | 5.82 | 9.08 | 9.54 | 9.72 |
| Inventory Days | 166.70 | 121.54 | 113.25 | 60.22 | 79.23 | 128.20 | 124.42 | 138.82 | 150.03 | 153.60 | 170.30 | 193.62 |
| Days Payable | 130.52 | 125.08 | 105.51 | 87.32 | 129.95 | 167.37 | 170.41 | 220.72 | 231.21 | 173.42 | 183.56 | 169.86 |
| Cash Conversion Cycle | 41.14 | 0.73 | 13.72 | -19.79 | -39.78 | -31.95 | -40.05 | -73.54 | -75.37 | -10.74 | -3.72 | 33.48 |
| Working Capital Days | -13.10 | -19.90 | -8.56 | -8.92 | -26.02 | -15.39 | -21.33 | -23.92 | -16.33 | 8.61 | 4.85 | 0.00 |
| ROCE % | 0.27% | -4.23% | 0.24% | 1.19% | 3.63% | 1.66% | 4.67% | 3.92% | 7.91% | 10.25% | 7.07% | 2.99% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.36 | 1.40 | 1.96 | 1.44 | 0.75 |
| Diluted EPS (Rs.) | 0.36 | 1.40 | 1.96 | 1.44 | 0.75 |
| Cash EPS (Rs.) | 1.80 | 3.19 | 3.39 | 2.64 | 1.87 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.85 | 28.57 | 27.69 | 26.26 | 25.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.85 | 28.57 | 27.69 | 26.26 | 25.34 |
| Dividend / Share (Rs.) | 0.00 | 0.50 | 0.50 | 0.50 | 0.50 |
| Revenue From Operations / Share (Rs.) | 23.83 | 23.18 | 22.62 | 18.71 | 15.56 |
| PBDIT / Share (Rs.) | 2.28 | 3.77 | 4.20 | 3.24 | 2.07 |
| PBIT / Share (Rs.) | 0.83 | 1.97 | 2.77 | 2.03 | 0.95 |
| PBT / Share (Rs.) | 0.66 | 1.93 | 2.72 | 1.97 | 0.95 |
| Net Profit / Share (Rs.) | 0.35 | 1.40 | 1.96 | 1.44 | 0.75 |
| PBDIT Margin (%) | 9.55 | 16.24 | 18.56 | 17.30 | 13.30 |
| PBIT Margin (%) | 3.48 | 8.51 | 12.22 | 10.87 | 6.10 |
| PBT Margin (%) | 2.78 | 8.32 | 12.01 | 10.52 | 6.15 |
| Net Profit Margin (%) | 1.49 | 6.04 | 8.66 | 7.67 | 4.84 |
| Return on Networth / Equity (%) | 1.23 | 4.90 | 7.08 | 5.46 | 2.97 |
| Return on Capital Employeed (%) | 2.78 | 6.79 | 9.91 | 7.57 | 3.69 |
| Return On Assets (%) | 1.06 | 4.37 | 6.45 | 4.84 | 2.64 |
| Asset Turnover Ratio (%) | 0.72 | 0.74 | 0.75 | 0.64 | 0.55 |
| Current Ratio (X) | 1.56 | 2.25 | 2.83 | 2.24 | 2.34 |
| Quick Ratio (X) | 1.04 | 1.74 | 2.30 | 1.84 | 2.03 |
| Inventory Turnover Ratio (X) | 14.08 | 2.81 | 3.28 | 3.19 | 2.61 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 35.67 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 15.65 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 64.33 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 84.35 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 13.34 | 80.42 | 89.47 | 52.56 | 66.35 |
| Interest Coverage Ratio (Post Tax) (X) | 3.05 | 30.86 | 42.80 | 24.38 | 23.91 |
| Enterprise Value (Cr.) | 141.22 | 110.46 | 112.37 | 102.10 | 77.22 |
| EV / Net Operating Revenue (X) | 2.85 | 2.29 | 2.39 | 2.62 | 2.39 |
| EV / EBITDA (X) | 29.83 | 14.10 | 12.87 | 15.17 | 17.93 |
| MarketCap / Net Operating Revenue (X) | 2.93 | 2.44 | 2.57 | 2.85 | 2.69 |
| Retention Ratios (%) | 0.00 | 64.32 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.42 | 1.98 | 2.10 | 2.03 | 1.65 |
| Price / Net Operating Revenue (X) | 2.93 | 2.44 | 2.57 | 2.85 | 2.69 |
| EarningsYield | 0.01 | 0.02 | 0.03 | 0.02 | 0.01 |
After reviewing the key financial ratios for Lotus Eye Hospital & Institute Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 5. It has decreased from 1.40 (Mar 24) to 0.36, marking a decrease of 1.04.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 5. It has decreased from 1.40 (Mar 24) to 0.36, marking a decrease of 1.04.
- For Cash EPS (Rs.), as of Mar 25, the value is 1.80. This value is below the healthy minimum of 3. It has decreased from 3.19 (Mar 24) to 1.80, marking a decrease of 1.39.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.85. It has increased from 28.57 (Mar 24) to 28.85, marking an increase of 0.28.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.85. It has increased from 28.57 (Mar 24) to 28.85, marking an increase of 0.28.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 0.50 (Mar 24) to 0.00, marking a decrease of 0.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 23.83. It has increased from 23.18 (Mar 24) to 23.83, marking an increase of 0.65.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.28. This value is within the healthy range. It has decreased from 3.77 (Mar 24) to 2.28, marking a decrease of 1.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.83. This value is within the healthy range. It has decreased from 1.97 (Mar 24) to 0.83, marking a decrease of 1.14.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.66. This value is within the healthy range. It has decreased from 1.93 (Mar 24) to 0.66, marking a decrease of 1.27.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 2. It has decreased from 1.40 (Mar 24) to 0.35, marking a decrease of 1.05.
- For PBDIT Margin (%), as of Mar 25, the value is 9.55. This value is below the healthy minimum of 10. It has decreased from 16.24 (Mar 24) to 9.55, marking a decrease of 6.69.
- For PBIT Margin (%), as of Mar 25, the value is 3.48. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 3.48, marking a decrease of 5.03.
- For PBT Margin (%), as of Mar 25, the value is 2.78. This value is below the healthy minimum of 10. It has decreased from 8.32 (Mar 24) to 2.78, marking a decrease of 5.54.
- For Net Profit Margin (%), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 5. It has decreased from 6.04 (Mar 24) to 1.49, marking a decrease of 4.55.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 15. It has decreased from 4.90 (Mar 24) to 1.23, marking a decrease of 3.67.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.78. This value is below the healthy minimum of 10. It has decreased from 6.79 (Mar 24) to 2.78, marking a decrease of 4.01.
- For Return On Assets (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has decreased from 4.37 (Mar 24) to 1.06, marking a decrease of 3.31.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has decreased from 0.74 (Mar 24) to 0.72, marking a decrease of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 2.25 (Mar 24) to 1.56, marking a decrease of 0.69.
- For Quick Ratio (X), as of Mar 25, the value is 1.04. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.04, marking a decrease of 0.70.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 14.08. This value exceeds the healthy maximum of 8. It has increased from 2.81 (Mar 24) to 14.08, marking an increase of 11.27.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 35.67 (Mar 24) to 0.00, marking a decrease of 35.67.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 15.65 (Mar 24) to 0.00, marking a decrease of 15.65.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 64.33 (Mar 24) to 0.00, marking a decrease of 64.33.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 84.35 (Mar 24) to 0.00, marking a decrease of 84.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 13.34. This value is within the healthy range. It has decreased from 80.42 (Mar 24) to 13.34, marking a decrease of 67.08.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.05. This value is within the healthy range. It has decreased from 30.86 (Mar 24) to 3.05, marking a decrease of 27.81.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.22. It has increased from 110.46 (Mar 24) to 141.22, marking an increase of 30.76.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.85. This value is within the healthy range. It has increased from 2.29 (Mar 24) to 2.85, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 29.83. This value exceeds the healthy maximum of 15. It has increased from 14.10 (Mar 24) to 29.83, marking an increase of 15.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.93, marking an increase of 0.49.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 64.32 (Mar 24) to 0.00, marking a decrease of 64.32.
- For Price / BV (X), as of Mar 25, the value is 2.42. This value is within the healthy range. It has increased from 1.98 (Mar 24) to 2.42, marking an increase of 0.44.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.93. This value is within the healthy range. It has increased from 2.44 (Mar 24) to 2.93, marking an increase of 0.49.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lotus Eye Hospital & Institute Ltd:
- Net Profit Margin: 1.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.78% (Industry Average ROCE: 10.6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.23% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.05
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 439 (Industry average Stock P/E: 134.38)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | S.F No.770/12, Avinashi Road, Coimbatore Tamil Nadu 641014 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Kavetha Sundaramoorthy | Chairman |
| Ms. Sangeetha Sundaramoorthy | Managing Director |
| Dr. K S Ramalingam | WholeTime Director & CEO |
| Mr. Karthik Veeramani | Director |
| CA. Perumalsamy Mahendran | Director |
| Dr. S Natesan | Director |
FAQ
What is the intrinsic value of Lotus Eye Hospital & Institute Ltd?
Lotus Eye Hospital & Institute Ltd's intrinsic value (as of 29 January 2026) is ₹94.59 which is 32.91% lower the current market price of ₹141.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹294 Cr. market cap, FY2025-2026 high/low of ₹141/55.0, reserves of ₹39.82 Cr, and liabilities of ₹71.51 Cr.
What is the Market Cap of Lotus Eye Hospital & Institute Ltd?
The Market Cap of Lotus Eye Hospital & Institute Ltd is 294 Cr..
What is the current Stock Price of Lotus Eye Hospital & Institute Ltd as on 29 January 2026?
The current stock price of Lotus Eye Hospital & Institute Ltd as on 29 January 2026 is ₹141.
What is the High / Low of Lotus Eye Hospital & Institute Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lotus Eye Hospital & Institute Ltd stocks is ₹141/55.0.
What is the Stock P/E of Lotus Eye Hospital & Institute Ltd?
The Stock P/E of Lotus Eye Hospital & Institute Ltd is 439.
What is the Book Value of Lotus Eye Hospital & Institute Ltd?
The Book Value of Lotus Eye Hospital & Institute Ltd is 29.2.
What is the Dividend Yield of Lotus Eye Hospital & Institute Ltd?
The Dividend Yield of Lotus Eye Hospital & Institute Ltd is 0.00 %.
What is the ROCE of Lotus Eye Hospital & Institute Ltd?
The ROCE of Lotus Eye Hospital & Institute Ltd is 2.99 %.
What is the ROE of Lotus Eye Hospital & Institute Ltd?
The ROE of Lotus Eye Hospital & Institute Ltd is 1.22 %.
What is the Face Value of Lotus Eye Hospital & Institute Ltd?
The Face Value of Lotus Eye Hospital & Institute Ltd is 10.0.